Clovis Oncology, Inc.
5500 Flatiron Parkway, Suite 100
Boulder, CO 80301
May 5, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Jordan Metoyer and Ada D. Sarmento
Re: Clovis Oncology, Inc.—Request for Acceleration
Registration Statement on Form S-3
(File No. 333-253485)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Clovis Oncology, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 (the “Registration Statement”) be accelerated to May 7, 2021 at 5:30 p.m. Eastern Time or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Sincerely,
| Clovis Oncology, Inc. | ||
| By: | /s/ Paul Gross | |
| Name: | Paul Gross | |
| Title: | Executive Vice President and General Counsel | |
| cc: | Thomas Mark, Esq., Willkie Farr & Gallagher LLP |
